液体活检在胰腺导管腺癌患者中应用的实用性。
Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma.
机构信息
Department of Gastroenterology and Hepatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine , Okayama , Japan.
出版信息
Cancer Biol Ther. 2019;20(10):1348-1353. doi: 10.1080/15384047.2019.1638685. Epub 2019 Jul 22.
In recent years, liquid biopsy for blood and body fluid in cancer patients has attracted attention. However, there have been few reports of liquid biopsy focusing on urine of pancreatic ductal adenocarcinoma (PDAC). In 56 patients with PDAC, DNA was extracted from urine and plasma prior to treatment, and KRAS mutations were analyzed with droplet digital PCR to examine the mutation detection rate. Our study showed that KRAS mutations were found in 27 cases (48%) in urine and 27 cases (48%) in plasma. The detection rate of urine KRAS mutations varied by renal functions. The rates were 70% (14/20) and 36% (13/36) in the creatinine clearance rate (CCr) < 70 mL/min group and in the CCr ≥ 70 mL/min group, respectively ( = .024). Whereas, no influence of the CCr was observed in the detection rates of plasma KRAS mutations. The rates were 50% (10/20) and 47% (17/36) in cases with the CCr < 70 mL/min group and the CCr ≥ 70 mL/min group, respectively. Although the sample size was small, this study clearly indicated a new possibility of less invasive urine liquid biopsy in PDAC patients.
近年来，针对癌症患者血液和体液的液体活检受到了关注。然而，针对胰腺导管腺癌（PDAC）尿液的液体活检研究较少。本研究对 56 例 PDAC 患者进行了前瞻性研究，在治疗前分别从尿液和血浆中提取 DNA，采用液滴数字 PCR 分析 KRAS 基因突变，以检测突变的检出率。我们的研究表明，尿液中 KRAS 基因突变 27 例（48%），血浆中 KRAS 基因突变 27 例（48%）。尿液 KRAS 基因突变的检出率与肾功能有关。在 CCr＜70ml/min 组和 CCr≥70ml/min 组，其检出率分别为 70%（14/20）和 36%（13/36）（=0.024）。而血浆 KRAS 基因突变的检出率不受 CCr 的影响。在 CCr＜70ml/min 组和 CCr≥70ml/min 组，其检出率分别为 50%（10/20）和 47%（17/36）。尽管样本量较小，但本研究清楚地表明 PDAC 患者进行微创性尿液液体活检具有新的可能性。
Zotero 插件